denibulin

11/01/2005 - "We examined the efficacy of a novel VDA, MN-029, in the rodent KHT sarcoma model. "

11/01/2005 - "A significant reduction in the functional vessel number was observed after intraperitoneal injection of MN-029 at a dose of 100 mg/kg. Histological evaluation showed extensive necrosis (approximately 90%) by 24 h. "

08/01/2010 - "A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors."
10/01/2011 - "MN-029 was generally well tolerated and showed decrease in tumor vascular parameters. "
11/01/2005 - "MN-029 treatment to the tumor-bearing mice also resulted in a dose-dependent tumor cell killing. "
11/01/2005 - "The results demonstrated that MN-029 could cause rapid vascular shutdown in solid tumors, dose-dependent secondary tumor cell killing, and effective enhancement of the antitumor effects of radiation and cisplatin chemotherapy."
11/01/2005 - "When used in combination with radiation or cisplatin chemotherapy, a 100 mg/kg dose of MN-029 significantly enhanced tumor killing compared to that seen with radiation or cisplatin alone. "

08/01/2010 - "One patient developed acute substernal chest pain 4 days after his first dose of MN-029 and was removed from the study. "

10/01/2011 - "The most common toxicities of MN-029 included nausea and vomiting (which appeared to be dose related), diarrhea, fatigue, headache, and anorexia. "